Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)

Employee Town Hall January 12, 2021 Filed by Cantel Medical Corp. Pursuant to Rule 425 under the Securities Act of 1933 and deemed to be filed pursuant to Rule 14a - 12 under the Securities Exchange Act of 1934 Subject Company: Cantel Medical Corp. Commission File No.: 001 - 31337 Date: January 12, 2021

Important Information for Investors and Shareholders This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitati on of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful pri or to registration or qualification under the securities laws of any such jurisdiction. In connection with the proposed merger between STERIS and Cantel, STERIS will file with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S - 4 that will include a proxy statement of Cantel that also constitutes a prospectus of STERIS. The definitive proxy statement/prospectus will be delivered to shareholders of Cantel. INVESTORS AND SECURITY HOLDERS OF STERIS AND CANTEL ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the registration statemen t a nd the definitive proxy statement/prospectus (when available) and other documents filed with the SEC by STERIS and Cantel through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by STERIS will be available free of charge on STERIS’s internet website at www.STERIS.com or by contacting STERIS’s Investor Relations Department at ( 440) 392 - 7245. Copies of the documents filed with the SEC by Cantel will be available free of charge on Cantel’s internet website at www.cantelmedical.com or by contacting Cantel’s Investor Rel ati ons Department at (763 ) 553 - 3341. Participants in the Merger Solicitation STERIS, Cantel, their respective directors and certain of their respective executive officers and employees may be considered partici pan ts in the solicitation of proxies in connection with the proposed transaction. Information regarding the persons who may, under the rul es of the SEC, be deemed participants in the solicitation of Cantel shareholders in connection with the proposed merger will be set forth in th e p roxy statement/prospectus when it is filed with the SEC. Information about the directors and executive officers of Cantel is set f ort h in its proxy statement for its 2020 annual meeting of stockholders, which was filed with the SEC on November 18, 2020 and certain of its Current Rep ort s on Form 8 - K. Information about the directors and executive officers of STERIS is set forth in its proxy statement for its 2020 annual meeting of stockholders, which was filed with the SEC on June 5, 2020 and certain of its Current Reports on Form 8 - K. Additional information regarding the part icipants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus filed with the above - referenced registration statement on Form S - 4 and other relevant materials to be filed with the SEC when they become available.

Cautionary Statement Regarding Forward - Looking Statements This communication contains “forward - looking statements” as that term is defined under the Private Securities Litigation Reform Act of 1995 and other securities laws, for which we claim the protection of the safe harbor for forward - looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward - looking statements includ e, but are not limited to, statements about the benefits of the acquisition of Cantel by STERIS, including future financial and operating results, Cantel’s or STERIS’s plans, objectives, expectations and intentions and the expected timing of completion of the transaction. These statements are based on current expectations, estimates, or forecasts about our businesses, the industries in which we operat e, and the current beliefs and assumptions of management; they do not relate strictly to historical or current facts. Without limiting t he foregoing, words or phrases such as “expect,” “anticipate,” “goal,” “project,” “intend,” “plan,” “believe,” “seek,” “may,” “could,” “ena ble ,” and “opportunity” and variations of such words and similar expressions generally identify forward - looking statements. Risks and unce rtainties associated with these forward - looking statements include the potential that we may not be able to consummate the transaction, or that the expected benefits and opportunities of the transaction may not be realized or may take longer to realize than expected, or th at required regulatory approvals may not be obtained as quickly as expected, or at all. There are also risks and uncertainties related to th e subsequent integration of the companies; the ability to recognize the anticipated synergies and benefits of the acquisition; restructuri ng in connection with, and successful closing of, the transaction; the ability to obtain required regulatory approvals for the transaction (in clu ding the approval of antitrust authorities necessary to complete the acquisition); the timing of obtaining such approvals and the risk th at such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefit s o f the transaction; the ability to obtain the requisite Cantel shareholder approval; the risk that a condition to closing of the tra nsa ction may not be satisfied on a timely basis or at all; the failure of the transaction to close for any other reason; risks relating to the va lue of the STERIS shares to be issued in the transaction; access to available financing (including financing for the transaction) on a timely b asi s and on reasonable terms; the impact of competitive products and pricing; the impact of the COVID - 19 pandemic on our operations and fina ncial results; general economic conditions; and technological and market changes in our industry. We caution that undue reliance sh oul d not be placed on such forward - looking statements, which speak only as of the date made. Some of the factors which could cause results t o differ from those expressed in any forward - looking statement are set forth in our most recent Annual Report on Form 10 - K, which we may update in Quarterly Reports on Form 10 - Q we have filed or will file hereafter. We expressly disclaim any obligation or undertaking to r elease publicly any updates or revisions to any forward - looking statements contained herein to reflect any change in our expectations w ith regard thereto or any change in events, conditions or circumstances on which any such statement is based. This cautionary statement is applicable to all forward - looking statements contained in this communication.

Coming Together to Create a Leading Global Infection Prevention and Control Solutions Provider +

STERIS Company Overview STERIS is a leading global provider of infection prevention and other procedural products and services serving a broad range of healthcare Customers 4 Customers Across Healthcare Sector Global workforce Hospital, Surgery & GI Centers Medical Device Manufacturers 13,000 associates with Customers across 100 countries, headquartered in Mentor, OH Shared Mission STERIS is built on Customer - centric values , with a mission to help its Customers create a healthier and safer world Pharmaceutical Production

CANTEL and STERIS –– A Great Fit 5 Enhanced Portfolio with Solutions Across Healthcare Setting Expanded Global Reach Combining our complementary portfolios will create a stronger global player with a comprehensive portfolio of solutions across endoscopy, dental and life sciences Will leverage STERIS’s strong international presence and broad footprint to extend the reach of Cantel’s solutions STERIS’s long - standing Customer relationships and substantial commercial infrastructure provides significant opportunities Better Serve Customers Expanding the Complete Circle of Protection

6 What This Means for Employees STERIS shares our values of safety, integrity, mutual respect and supporting employees and customers Expect to create career development opportunities for Cantel employees as part of a larger global organization We are taking a major leap forward toward achieving our goals This Transaction is About Growth for Our Business and Employees

What Happens Next? The transaction is expected to close by the end of June 2021 Representatives from Cantel and STERIS will form a transition team to plan on how best to bring our companies together Until close, Cantel and STERIS will remain separate companies. This means that we will continue to operate as usual We are committed to transparency and will provide updates as appropriate as we move through this process Continue to Execute our Plan and Serve Our Customers Announcement is first step in a process